Collegium Pharmaceutical (COLL) Competitors $33.39 -0.44 (-1.30%) Closing price 04:00 PM EasternExtended Trading$33.39 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. CRNX, PTGX, KYMR, MLTX, AKRO, ADMA, SRRK, MIRM, ACAD, and ZLABShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), MoonLake Immunotherapeutics (MLTX), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), ACADIA Pharmaceuticals (ACAD), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. Its Competitors Crinetics Pharmaceuticals Protagonist Therapeutics Kymera Therapeutics MoonLake Immunotherapeutics Akero Therapeutics ADMA Biologics Scholar Rock Mirum Pharmaceuticals ACADIA Pharmaceuticals Zai Lab Crinetics Pharmaceuticals (NASDAQ:CRNX) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings. Does the media refer more to CRNX or COLL? In the previous week, Crinetics Pharmaceuticals had 10 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 11 mentions for Crinetics Pharmaceuticals and 1 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.34 beat Crinetics Pharmaceuticals' score of 0.39 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CRNX or COLL? Crinetics Pharmaceuticals presently has a consensus price target of $74.45, suggesting a potential upside of 75.19%. Collegium Pharmaceutical has a consensus price target of $42.33, suggesting a potential upside of 26.78%. Given Crinetics Pharmaceuticals' higher possible upside, equities research analysts plainly believe Crinetics Pharmaceuticals is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, CRNX or COLL? Collegium Pharmaceutical has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.39M2,875.34-$298.41M-$4.11-10.34Collegium Pharmaceutical$707.01M1.49$69.19M$1.0432.11 Is CRNX or COLL more profitable? Collegium Pharmaceutical has a net margin of 5.13% compared to Crinetics Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 97.28% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -32.28% -29.45% Collegium Pharmaceutical 5.13%97.28%13.87% Do insiders and institutionals have more ownership in CRNX or COLL? 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, CRNX or COLL? Crinetics Pharmaceuticals has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. SummaryCollegium Pharmaceutical beats Crinetics Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.05B$2.68B$6.10B$10.52BDividend YieldN/A53.56%5.51%4.70%P/E Ratio32.1123.8685.6826.85Price / Sales1.49613.34585.01185.67Price / Cash2.8028.3526.3031.10Price / Book4.705.5913.256.72Net Income$69.19M$32.78M$3.30B$276.44M7 Day Performance-4.57%5.24%4.70%3.13%1 Month Performance-12.87%10.87%8.43%10.21%1 Year Performance-16.11%-1.45%88.01%40.35% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical4.1568 of 5 stars$33.39-1.3%$42.33+26.8%-19.2%$1.05B$707.01M32.11210Positive NewsCRNXCrinetics Pharmaceuticals3.8905 of 5 stars$43.51-5.2%$73.20+68.2%-21.6%$4.32B$1.04M-10.59210PTGXProtagonist Therapeutics2.121 of 5 stars$65.14-3.4%$68.36+4.9%+44.6%$4.19B$434.43M93.06120Positive NewsAnalyst ForecastKYMRKymera Therapeutics2.0519 of 5 stars$58.50+4.0%$59.95+2.5%+33.7%$4.02B$47.07M-16.86170MLTXMoonLake Immunotherapeutics2.957 of 5 stars$6.24-89.9%$57.00+813.5%-84.3%$3.98BN/A-2.242Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeAKROAkero Therapeutics3.6968 of 5 stars$47.62-0.3%$81.14+70.4%+63.0%$3.82BN/A-23.8130ADMAADMA Biologics3.7552 of 5 stars$14.70-5.8%$27.67+88.2%-30.7%$3.73B$426.45M17.09530SRRKScholar Rock4.3366 of 5 stars$38.36-1.0%$46.40+21.0%+436.4%$3.72B$33.19M-13.18140MIRMMirum Pharmaceuticals3.4894 of 5 stars$72.85+0.1%$76.50+5.0%+84.7%$3.66B$336.89M-60.21140ACADACADIA Pharmaceuticals4.4762 of 5 stars$21.32+1.3%$29.12+36.6%+43.0%$3.55B$957.80M16.03510ZLABZai Lab2.8365 of 5 stars$32.93+4.1%$56.35+71.1%+26.4%$3.53B$398.99M-16.141,869Positive News Related Companies and Tools Related Companies CRNX Competitors PTGX Competitors KYMR Competitors MLTX Competitors AKRO Competitors ADMA Competitors SRRK Competitors MIRM Competitors ACAD Competitors ZLAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
